IL2 and neoplasm: In ACT trials using high dose IL-2 no correlation between tumor burden and clinical response has been observed previously [9] and whether our findings are due to the lower amount of IL-2 given or whether it might just be a coincidence considering the low number of patients treated can not be concluded in this pilot study.